ZyCal Bioceuticals Researches Ostinol for Bone, Joint Health

TOMS RIVER, N.J.—ZyCal Bioceuticals Healthcare Co. recently began a series of clinical and preclinical trials on bones and joints to evaluate the health benefits of Ostinol, powered by Cyplexinol—Nature’s BMP Complex.

Preclinical trials comparing Cyplexinol to other bone and joint ingredients found it is the only bioactive osteoinductive compound, meaning it can turn stem cells into bone- and cartilage-building cells.

There are seven ongoing human clinical trials and four completed trials, which occurred during the past 18 months to evaluate the impact of Ostinol on overall bone and joint health. The studies investigated Ostinol’s effect on bone density in post-menopausal, osteoporotic women; the effects on people with degenerative joint disease; and the effects on people with moderate to severe osteoarthritis.